Table 1.
Patient Characteristics
| All | Late arm | Early arm | p | |
|---|---|---|---|---|
| n | 30 | 16 | 14 | |
| Age at discovery(mean) | 57.3 | 56.8 | 57.9 | 0.75 |
| Gender | ||||
| Male (n,%) | 19 (63%) | 8 (50%) | 11 (79%) | 0.11 |
| Female (n, %) | 11 (37%) | 8 (50%) | 3 (21%) | |
| Race | ||||
| Caucasian (white, non-Hispanic) | 30 (100%) | 16 (100%) | 14 (100%) | - |
| KPS at enrollment | ||||
| mean KPS score (SD) | 84 (±9) | 81 (±10) | 88 (±7) | 0.07 |
| Steroids pre-LITT | ||||
| on Dexamethasone (n,%) | 7 (23%) | 5 (31%) | 2 (14%) | 0.27 |
| Tumor | ||||
| WHO grade IV (n,%) | 30 (100%) | 16 (100%) | 14 (100%) | - |
| Frontline/initial surgery | ||||
| Gross total (n,%) | 23 (77%) | 12 (75%) | 11 (79%) | 0.82 |
| Subtotal (n,%) | 3 (10%) | 1 (6%) | 2 (14%) | 0.46 |
| Biopsy (n,%) | 4 (13%) | 3 (19%) | 1 (7%) | 0.35 |
| MGMTp status | ||||
| Unmethylated | 16 (53%) | 7 (44%) | 9 (64%) | 0.26 |
| Methylated | 11 (37%) | 7 (44%) | 4 (29%) | 0.39 |
| Indeterminate | 3 (10%) | 2 (12%) | 1 (7.1%) | 0.63 |
| IDH1 status | ||||
| Wildtype | 28 (93%) | 14 (88.5%) | 14 (100%) | 0.17 |
| Mutated | 0 (0%) | 0 (0%) | 0 (0%) | - |
| Unknown | 2 (7%) | 2 (12.5%) | 0 (0%) | 0.17 |
Demographic and tumor characteristics of analyzed individuals of the Late Arm (doxorubicin 6 weeks after LITT) or Early Arm (doxorubicin a week after LITT). P values reflect between group comparisons using unpaired t-tests for continuous variables and chi-square tests between categorical values. Both groups received identical median doses of doxorubicin (n = 6). Additional details available in Supplementary Table 1.